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Abstract
Objective: Diabetes technology is available and its efficacy and safety have been
demonstrated; however, there is little evidence as to how this technology is being utilized and its effectiveness in vulnerable populations. This study evaluated differences
in outcomes for young adults in the United States (U.S.) from lower socioeconomic
(SES) backgrounds with type 1 diabetes (T1D) managed on continuous subcutaneous
insulin infusion (CSII) versus multiple daily injections (MDI) or fixed-dose insulin (FDI).
Research design, methods and participants: Utilizing the Optum® de-
identified
Electronic Health Record data set between 2008 and 2018 to perform a retrospective,
cohort study, we identified 805 subjects with T1D aged 18–30 years with Medicaid.
We evaluated median difference in HbA1c between CSII and MDI/FDI users for
24 months. Predictors of diabetic ketoacidosis (DKA)-associated hospitalizations by
CSII use were evaluated using logistic regression.
Results: CSII users showed statistically significant lower median HbA1c values at
24 months of follow-up compared to individuals on MDI/FDI. Non-white individuals
were at lower odds of receiving treatment with CSII. Subjects on CSII were not more
likely to be hospitalized for DKA compared to subjects treated with MDI/FDI. Older
subjects were at lower odds of being hospitalized for DKA. Males and subjects followed by Endocrinologists were at higher odds of being hospitalized for DKA.
Conclusions: Young adults with T1D from lower SES backgrounds show improved
glycaemic control when in CSII compared to MDI/FDI without increases in hospitalizations for DKA.
KEYWORDS

continuous subcutaneous insulin infusion, insulin pump, medicaid, socioeconomic status, type
1 diabetes
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I NTRO D U C TI O N

subcutaneous insulin infusion (CSII), continuous glucose monitoring (CGM), sensor augmented pumps (SAP) and hybrid closed-loop

The treatment of type 1 diabetes (T1D) is rapidly evolving with

(HCL) systems.1 Despite these exciting advances, adoption of these

the development of novel technologies such as continuous

technologies and access to them has not permeated to all segments
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of the population. 2,3 Large database and registry data have demon-

technology trials to date and some studies do not even list baseline

strated that many youth and young adults with T1D do not meet

demographics.13,14 Additionally, it appears that there are clear racial

established haemoglobin A1c (HbA1c) goals.

4,5

In fact, according to

and ethnic biases regarding who receives newer technologies even

data from the T1D Exchange Registry, between 2016 and 2018, only

when controlling for SES.3 The data regarding racial and ethnic bi-

17% of youth achieved the American Diabetes Association (ADA)

ases are predominantly from the paediatric literature. In a study by

6

HbA1c goal <7.5%. While reasons for poor glycaemic control in this

Willi et al using data from the T1D Exchange Clinic Network, fewer

group are multifactorial, lack of diabetes technology utilization may

Black compared to white children across all income strata were on

play a role.

insulin pumps. Higher HbA1c values were seen even in high-income

Diabetes technologies as stand-alone insulin pumps and CGMs

Black families, perhaps because fewer of them were managed with

in addition to systems in which the pump and sensor fully commu-

insulin pump therapy. Black children with private insurance were less

nicate are being increasingly utilized to treat T1D. After almost four

likely to be on insulin pumps compared with white children without

decades since insulin pumps became commercially available starting

private insurance.3 In another study in a paediatric population of

with Medtronic's Minimed 502 in 1983, there are substantial data

subjects with T1D by Lin et al, subjects of non-Hispanic white race

that individuals with T1D on CSII demonstrate better HbA1c out-

and higher socioeconomic status were more likely to be placed on

comes compared to MDI.7 Furthermore, subjects with T1D on CSII

pumps in the first year following diagnosis.19 In a recent study ex-

demonstrate improvements in microvascular outcomes including

amining racial-ethnic inequity in young adults with T1D, Black young

retinopathy and peripheral neuropathy compared to management

adults had the lowest insulin pump use, despite similar rates of pub-

8

with multiple daily injections (MDI). CGM was next to make its way

lic insurance as Hispanic young adults. 20

to the T1D community and has demonstrated numerous benefits

When diabetes technology companies reach out to insurance

including HbA1c reduction, reduction of glycaemic variability and

companies through their managed care teams, they lobby for cover-

less hypoglycaemia.9,10 Moreover, individuals with CGM who are

age of devices by showing clinical outcome data. Medicaid is health

switched from MDI to CSII spend more time in range (TIR) defined

care in the United States funded by individual states and the federal

as the glucose concentration 70–180 mg/dL compared to those on

government to eligible low-income children, adults, pregnant women

CGM and MDI.11 Results seem to improve further the more auto-

and people with disabilities. There is variable coverage of diabetes

mated the system, as seen in SAP therapy which has been shown

technology for individuals with T1D depending on the state in which

12

to reduce HbA1c and time spent in hypoglycaemia.

Most recently,

they reside and according to individual Medicaid plan. In order to

HCL systems are available and illustrate encouraging time in range

expand insurance coverage for diabetes technology and provide

data.13,14

more emphasis for why racial-ethnic biases in prescribing patterns

While CSII, CGM, SAP and HCL systems have demonstrated

of diabetes technology need further investigation, data on clinical

real benefit in T1D patients, there are no uniform guidelines or

outcomes in a lower socioeconomic young adult patient population

treatment algorithms within the United States to guide practi-

with T1D need to be shown.

tioners regarding how to best deploy these technologies to the

This study evaluated whether young adults on Medicaid with

patients who would benefit most. According to the American

T1D had better clinical outcomes as defined by HbA1c and hospital-

Diabetes Association (ADA) 2021 guidelines, insulin pump ther-

izations for diabetic ketoacidosis (DKA) when on CSII compared to

apy may be considered for all adults and youth with T1D who

subjects on MDI or fixed-dose insulin (FDI).

can safely manage the device.15 This guidance is inconsistent
with older Endocrine Society 2016 and American Association of
Clinical Endocrinologists (AACE) 2018 guidelines which included
more restrictions around the definition of an ideal pump candidate.16,17 Even in countries with nationalized healthcare systems
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2.1 | Data source

and guidance on who qualifies for pump therapy, there is low utilization of such devices. For instance, the National Institute for

We performed a retrospective cohort study using the Optum® de-

Health and Clinical Excellence (NICE) published guidelines for CSII

identified Electronic Health Record (EHR) data set. 21 The data set

use in 2008 in the United Kingdom (NICE TA151, UK Best Practice

contained EHR data from 5 million adults (age 18 and older), nation-

Guide). Despite these recommendations, an audit in 2011 revealed

ally distributed across the United States. EHR data contains ICD-9

18

an estimated prevalence of 6% for CSII utilization.

and ICD-10 codes, prescription medication orders, vital signs, lab-

While diabetes technology is available and the data regarding

oratory results, procedure codes and demographic measures. The

its efficacy and safety have also been demonstrated, what has not

Optum® de-identified EHR data set pulls electronic medical records

been extensively shown is what adult cohort of the T1D community

from integrated delivery networks and facilities spanning the United

is accessing these treatment modalities and what influences their

States and processes and standardizes field for use in research. The

availability especially to the most vulnerable groups of the T1D

data are longitudinal and have been used in hundreds of publications

population. It does not appear that there is much diversity in the

in multiple disease areas including diabetes. 22
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2.2 | Study sample
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Blacks, Asians and other races were grouped into one racial category and compared to whites in this analysis. Ethnicity was also

The study sample was limited to T1D patients with an encounter

re-categorized into Hispanics vs. other ethnicities. Subjects making

between 2008 and 2018 and had activity for at least two years after

less than $45,000 a year were considered low-income individuals.

first encounter date. Subjects aged 18 to 30 years, on Medicaid,

Because adult Endocrinologists may differ in their approach to pre-

and with a diagnosis of T1D were identified. Medicaid was used as a

scribing CSII to their patients when compared to physicians from

proxy for lower SES. 23 Subjects with a diagnosis code of pregnancy

other specialties, a composite variable was generated specifying if

and those who received glucose-lowering medications for type 2

the subject had at least one encounter with an adult Endocrinologist

diabetes (T2) were excluded from the analysis.

and was adjusted for in the analysis.

2.3 | Measures

2.7 | Statistical analyses

Prescription and diagnosis codes for all variables are listed under

Characteristics and outcomes of the study sample overall and

supplemental material.

stratified by CSII use are presented as medians and interquartile
ranges or frequencies and percentages, as appropriate. Bivariate

2.4 | Exposure

comparisons for all variables by CSII use were examined using the
Mann-W hitney U tests for continuous variables and Chi-s quare
tests for categorical variables. Differences in HbA1c between CSII

Treatment modality was classified as CSII versus MDI or FDI.

and MDI/FDI users were compared at baseline and at each deter-

Subjects were assigned to CSII or MDI or FDI based on encounter

mined interval for the 24-m onth follow-up period. Univariate and

diagnosis codes (see Table S1 for a list of diagnosis codes). For sub-

multivariable logistic regression analyses were used to identify

jects with a diagnosis code for CSII, the first record indicating CSII

factors associated with CSII prescription and DKA-related hospi-

was considered the date of insulin pump initiation. Patients on MDI

tal admissions. A histogram was used to illustrate the HbA1c at

and FDI were combined as the non-C SII group and were defined

6-m onth intervals. Model fitness was tested using the likelihood

using prescription codes, and the date of enrolment in the cohort

test. All tests were two-sided, and the alpha level of significance

was considered their treatment start date (see Table S2). All labo-

was set at 0.05. All analyses were done using SAS 9.4 (SAS Institute

ratory results and hospitalization data prior to this treatment start

Inc., Cary, NC, USA).

date were excluded from this analysis.

2.5 | Outcomes

3
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R E S U LT S

Demographic characteristics of the 805 subjects that met incluThe primary outcome was HbA1c (%) measurements obtained at

sion criteria are shown in Table 1. Overall, 65.8% were between

3–6, 7–12, 13–18 and 19–24 months following the assignment of

age 18 and 26 years, 54.9% were female, 64.6% were white, 8.5%

treatment modality. HbA1c values were considered if occurred at

were Hispanics and 77% reported annual household income

least 3 months after CSII prescription. We used the last HbA1c for

less than $45,000. Of the cohort, 45.1% were treated by adult

every patient with multiple HbA1c records per each 3-month inter-

Endocrinologists at least once. Subjects managed by CSII accounted

val. For graphical illustrations, laboratory data in the form of HbA1c

for 13% of the cohort. Subject characteristics by treatment modality

were analysed at 6-month intervals.

at first encounter are described in Table 1. When examining the dis-

The secondary outcome was hospitalization for DKA. Unique

tribution of subjects across the two treatment arms, there were dif-

DKA encounters were defined as an inpatient diagnosis code for

ferences in treatment modality by race and specialty follow-up. CSII

DKA corresponding to a distinct inpatient visit encounter ID. We

users were more likely to be white (84.8%) and followed by an adult

calculated the total number of unique DKA episodes of DKA per

Endocrinologist (66.7%). The number of enrollees by year along with

subject over the 24-month follow-up period.

the number of subjects with insulin pump initiation by year within
the cohort is shown in Table S3.

2.6 | Covariates

The median HbA1c in CSII users was 8.0% (IQR: 7.3–10.1) versus 9.5% in the MDI/FDI group (IQR: 8.0–11.6) (P = 0.021) at 19–
24 months of follow-up. Comparison of the median HbA1c levels by

We controlled for the age, race, ethnicity, gender and income of the

treatment modality at each follow-up point is illustrated in Table 2,

subject. Age was classified as 18–26 years and 27 or older at the

Figure 1.

time of first encounter. This was based on knowledge that paren-

Table 3 presents information on the number of DKA-associated

tal healthcare coverage for dependent children ends after age 26.

hospitalizations. No significant differences were found in DKA
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Baseline Characteristics

TA B L E 1 Demographic Characteristics
(N = 805)

All

CSII

MDI/Fixed

N, %

N, % (105,
13.0)

N, % (700,
87.0)

P-value

0.050

Age (in years)
18–26

530 (65.8)

78 (74.3)

452 (64.6)

27–3 0

275 (34.2)

27 (25.7)

248 (35.4)

Female

442 (54.9)

63 (60.0)

379 (54.1)

Male

363 (45.1)

42 (40.0)

321 (45.9)

White

520 (64.6)

89 (84.8)

431 (61.6)

Other Races

285 (35.4)

16 (15.2)

269 (38.4)

68 (8.5)

4 (3.8)

64 (9.1)

737 (91.5)

101 (96.2)

636 (90.9)

$45,000+

185 (23.0)

20 (19.1)

165 (23.6)

<$45,000

620 (77.0)

85 (80.9)

535 (76.4)

Endocrinology

363 (45.1)

70 (66.7)

293 (41.9)

Other Specialties

442 (54.9)

35 (33.3)

407 (58.1)

Gender
0.261

Race
<.0001

Ethnicity
Hispanic
Other Ethnicities

0.067

Income
0.304

Specialty
<.0001

Note: Chi-Square test.
Values in bold font indicate significance at 0.05.

TA B L E 2 Median HbA1c (%) (within 24 months of follow-up) by
treatment modality
CSII
N

Median (IQR)

3 to 6

36

8.2 (7.3–9.3)

7 to 12

43

13 to 18
19 to 24

N

|

DISCUSSION

In our sample of young adults with T1D on Medicaid, we found that

MDI/FDI

Month

4

median HbA1c levels were statistically significantly lower in individ-

Median (IQR)

P-value

77

9.0 (7.4–11.3)

0.065

low-up. These results are consistent with an analysis of randomized

8.3 (7.8–10.2)

126

9.0 (7.5–11.2)

0.265

clinical trials comparing CSII with MDI in subjects with T1D in which

38

8.2 (7.3–10.3)

126

9.2 (7.7–12.0)

0.041

CSII was shown to lead to statistically lower HbA1c values regard-

26

8.0 (7.3–10.1)

128

9.5 (8.0–11.6)

0.021

less of whether regular human insulin or rapid-acting analogue in-

Note: Mann-Whitney U test.
Values in bold font indicate significance at 0.05.

uals managed with CSII compared to MDI/FDI at 24 months of fol-

sulin was utilized.7 In addition to being statistically significant, the
difference between median HbA1c values in the CSII group versus
the MDI/FDI group is clinically relevant. According to landmark data

admissions between the CSII users and the MDI/FDI group

from the Diabetes Complications and Control Trial (DCCT) and the

during the 24-month follow-up period (31.4% vs 25.1%, P = 0.171

Epidemiology of Diabetes Interventions and Complications (EDIC)

respectively).

follow-up, intensive glucose control reduces the risk of microvascu-

Determinants of receiving CSII as a treatment modality are pre-

lar complications. 24 In fact, the risk reduction is non-linear, and thus,

sented in Table 4. Subjects followed by adult Endocrinologists were

even greater risk reduction is seen in those individuals with initial

more likely to receive insulin pump treatment (aOR = 2.67, 95% CI:

higher HbA1c levels. This is particularly meaningful in the lower SES

1.71, 4.15). Non-white subjects were at lower odds of receiving CSII

population that we describe, who if faced with further disabilities

(aOR = 0.30, 95% CI: 1.17, 0.52).

due to microvascular changes including blindness, dialysis and am-

Predictors of hospitalization for DKA within the 24-month fol-

putation, the further down on the socioeconomic ladder he or she

low-up period are shown in Table 5. Males were at higher odds of

will fall. Ultimately, this will create an economic burden and result in

hospitalization for DKA (aOR = 1.57, 95% CI: 1.14, 2.18). The odds

increased healthcare utilization.

of admission for DKA were higher among subjects seen by an adult

Risk for DKA was not greater in the CSII group; a significant

Endocrinologist in this cohort (aOR = 1.76, 95% CI: 1.27, 2.44). Older

finding given the reduced utilization of CSII in the Non-white pop-

subjects were at lower odds of DKA (aOR = 0.57, 95% CI: 0.40, 0.82).

ulation. It is possible that there is inherent bias by practitioners to
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3-6 m

7-12 m

13-18 m

5 of 7

19-24 m

F I G U R E 1 Mean HbA1c (± SD) stratified by time period and treatment modality. HbA1c: haemoglobin A1c, CSII: continuous
subcutaneous infusion, blue. MDI/FDI: multiple daily injections/fixed-dose insulin, red

TA B L E 3 Events of DKA (within 24 months of follow-up) by
treatment modality

TA B L E 4 Predictors of CSII Use (Logistic Regression).
cOR, 95%CI
(LL, UL)

aOR, 95%CI (LL,
UL)

Other Races
(reference = White)

0.29 (0.17,
0.50)

0.30 (0.17, 0.52)

Hispanic (reference = Non-
Hispanic / others)

0.39 (0.14,
1.10)

0.44 (0.15, 1.26)

27+ years
(reference = 18–26 years)

0.63 (0.40,
1.00)

0.66 (0.41, 1.06)

15 (2.1)

2 (1.9)

12 (1.7)

Male (reference = Female)

0.80 (0.52, 1.24)

5

0 (0.0)

9 (1.3)

0.79 (0.52,
1.20)

≥6

7 (6.7)

33 (4.7)

Low income (<$45,000)
(reference = $45,000+)

1.31 (0.78,
2.20)

1.53 (0.89, 2.61)

Yes

33 (31.4)

176 (25.1)

2.78 (1.80,
4.28)

2.67 (1.71, 4.15)

No

72 (68.6)

524 (74.9)

Endocrinologist
(reference = Other
Specialties)

CSII

MDI/Fixed

N, %

N, %

0

72 (68.6)

524 (74.9)

1

14 (13.3)

79 (11.3)

2

7 (6.7)

28 (4.0)

3

3 (1.9)

4

Number of DKA
Admissions

P
value

Hospitalization for DKA
0.171

Note: Values in bold font indicate statistical significance.

avoid prescribing CSII to Non-white individuals and low SES groups
due to a fear that those populations may not be able to success-

included following with an adult Endocrinologist which may be ex-

fully operate the technology. The lack of increased risk of DKA for

plained by the fact that typically more complex individuals with T1D

persons on CSII may provide more assurance to providers that they

follow with specialists. Male subjects were also at increased odds

can be prescribed to patients for whom technology has been histor-

for hospitalization for DKA which warrants further explanation.

ically withheld out of fear of adverse outcomes. Predictors of DKA

Older individuals were at less risk of DKA perhaps owing to more

23989238, 2021, 3, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/edm2.252, Wiley Online Library on [27/12/2022]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

|

MCKEE et al.

|

MCKEE et al.

TA B L E 5 Predictors of Hospitalizations for DKA within
24 months of follow-up (Logistic Regression).
cOR, 95%CI
(LL, UL)

aOR, 95%CI
(LL, UL)

CSII Use (reference = MDI/
FDI)

1.37 (0.87, 2.13)

1.13 (0.71, 1.81)

Other Races
(reference = White)

1.00 (0.72, 1.39)

1.03 (0.73, 1.45)

Hispanic (reference = Non-
Hispanic / others)

0.65 (0.35, 1.22)

0.63 (0.33, 1.20)

27+ years (reference = 18–
26 years)

0.59 (0.42, 0.84)

0.57 (0.40, 0.82)

Male (reference = Female)

1.51 (1.10, 2.07)

1.57 (1.14, 2.18)

Low income (<$45,000)
(reference = $45,000+)

1.47 (0.99, 2.19)

1.50 (0.99, 2.26)

Endocrinologist
(reference = Other
Specialties)

1.81 (1.32, 2.49)

1.76 (1.27, 2.44)

Note: Values in bold font indicate statistical significance.

examine the disparities in patient characteristics in each treatment
group in reference to HbA1c.
Another limitation of the study is that as investigators, we cannot account for the ever-changing differences in CSII coverage by
state and type of Medicaid insurance plan. CSII coverage changes
frequently over time, by state and by individual plan.
The healthcare implications of this study are important and
timely in an era of unprecedented advances in diabetes technology and a time of much discussion regarding social inequity in the
United States. Further examination and study of prescribing biases
and insurance boundaries to diabetes technology is needed. To make
informed decisions about diabetes technology in adults with T1D,
clinical trials that are more inclusive of minorities and those of lower
SES are needed.

5
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CO N C LU S I O N

Statistically significant and clinically relevant lower median HbA1c
values are seen in individuals on CSII versus MDI/FDI in this cohort

experience with CSII. Neither race nor ethnicity was a predictor for

of subjects with T1D on Medicaid. Further research into dispari-

hospitalization for DKA. These findings are in contrast to system-

ties in diabetes technology prescribing and predictors of successful

atic review examining predictors of DKA in adults with T1D which

CSII utilization in young adults with T1D from disadvantaged back-

showed prevalence of DKA decreased with increasing age but was

grounds is needed. Clinical trials involving diabetes technology

higher in non-white ethnicities. 25

should be more inclusive of young adults with T1D of lower SES.

Even though CSII has been available for several decades now,
there appears to be low technology utilization among young adults

AC K N OW L E D G E M E N T S

with T1D and lower SES. Additionally, the majority of individuals

This study was made possible by the Clinical Research Scholarship

with T1D in this cohort are followed by non-Endocrinologists, per-

Program (CRSP) and the Saint Louis University Department of

haps due to the shortage of clinical Endocrinologists and/or due to

Health and Clinical Research Outcomes.

the lack of commercial insurance on the part of the subjects. It is
possible that low technology utilization is influenced by the lack of

C O N FL I C T O F I N T E R E S T

encounters or access to specialist care.

The authors have no conflicts of interest relevant to this article to

CSII does not appear to be prescribed at similar rates to Non-

disclose.

white young adults with T1D from lower socioeconomic backgrounds
managed by Medicaid. The reason for this warrants further investi-

AU T H O R C O N T R I B U T I O N

gation. This finding is in keeping with data from the T1D Exchange

A.M. and S.A. wrote the research proposal. N.A. conducted the data

network which demonstrated large racial-ethnic inequity in young

analyses. L.H. edited the manuscript. A.M. and N.A. are the guaran-

adults with T1D, especially in Black participants. Compared to White

tors of the work, as such, had full access to the data in the study and

participants, fewer Black and Hispanic individuals utilized CSII, with

take responsibility for the integrity of the data and accuracy of the

Black young adults having the lowest rates and highest HbA1c lev-

analysis.

els.

20

T1D subjects on Medicaid followed by adult Endocrinologists

were more likely to receive CSII.

DATA AVA I L A B I L I T Y S TAT E M E N T

This study has limitations. Although it is recognized that in the

The data that support the findings of this study are available

real world, individuals with T1D may alternate between therapies;

from Optum® de-
identified Electronic Health Record data set.

treatment category was determined according the type of diabetes

Restrictions apply to the availability of these data, which were used

therapy at baseline entry in the study. The duration of 24-month

under licence for this study. Data are available from the correspond-

follow-up does not account for crossovers between therapies over

ing author with the permission of Optum® de-identified Electronic

time. However, using baseline treatment assignment is likely to bias

Health Record data set.

effect sizes towards the null. The results are also limited by the sample size and the number of available HbA1c values at each refer-

ORCID

ence point. If a larger sample was available, it would be interesting to
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S U P P O R T I N G I N FO R M AT I O N
Additional supporting information may be found online in the
Supporting Information section.
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